DLocal (NASDAQ:DLO – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has a $19.00 price objective on the stock, up from their previous price objective of $12.00. The Goldman Sachs Group’s price objective would indicate a potential upside of 20.03% from the stock’s current price.
DLO has been the subject of a number of other research reports. Citigroup raised their price objective on DLocal from $14.60 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Morgan Stanley set a $15.00 price target on DLocal in a report on Thursday, August 14th. Wall Street Zen downgraded shares of DLocal from a “strong-buy” rating to a “buy” rating in a report on Monday, September 22nd. UBS Group reaffirmed a “neutral” rating and issued a $10.00 price objective (up from $9.00) on shares of DLocal in a research report on Wednesday, July 30th. Finally, Truist Financial boosted their target price on shares of DLocal from $12.00 to $14.00 and gave the stock a “hold” rating in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, DLocal has a consensus rating of “Moderate Buy” and an average target price of $15.00.
Get Our Latest Report on DLocal
DLocal Stock Up 1.0%
DLocal (NASDAQ:DLO – Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.01. DLocal had a net margin of 16.90% and a return on equity of 36.85%. The company had revenue of $256.50 million during the quarter, compared to the consensus estimate of $226.71 million. During the same period last year, the firm earned $0.15 earnings per share. DLocal’s revenue was up 49.7% compared to the same quarter last year. DLocal has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that DLocal will post 0.47 EPS for the current fiscal year.
Hedge Funds Weigh In On DLocal
Several institutional investors and hedge funds have recently modified their holdings of DLO. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of DLocal by 603.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,053 shares of the company’s stock worth $34,000 after buying an additional 3,477 shares during the last quarter. Activest Wealth Management acquired a new position in DLocal in the second quarter valued at approximately $80,000. Caption Management LLC boosted its position in DLocal by 164.7% in the 1st quarter. Caption Management LLC now owns 11,249 shares of the company’s stock worth $94,000 after purchasing an additional 7,000 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of DLocal by 17.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,108 shares of the company’s stock worth $103,000 after purchasing an additional 1,329 shares during the period. Finally, CWM LLC purchased a new position in shares of DLocal during the 2nd quarter valued at approximately $113,000. Institutional investors and hedge funds own 90.13% of the company’s stock.
About DLocal
DLocal Limited operates a payment processing platform worldwide. The company offers pay-in solution which the business and get paid for their products and services through various payment methods, including international and local cards, online bank transfers and direct debit, cash, and alternative payment methods.
Further Reading
- Five stocks we like better than DLocal
- Most active stocks: Dollar volume vs share volume
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What is a Secondary Public Offering? What Investors Need to Know
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Dividend Payout Ratio Calculator
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for DLocal Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DLocal and related companies with MarketBeat.com's FREE daily email newsletter.